Simple Blood Test Enables More Informed Prostate Cancer Biopsy Decisions

Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry, has announced that it will exhibit its Prostate Health Index (phi) test at the 113th American Urological Association (AUA) Annual Meeting and Exhibition in San Francisco, Calif., May 18–21, 2018. Beckman Coulter’s Prostate Health Index (phi) and phi score help fill a need for better diagnostic testing to assist physicians in deciding if a prostate biopsy should be conducted to rule out prostate cancer. The phi score combines three automated blood tests into one index that estimates a man’s probability of having prostate cancer found on biopsy.

A recent study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer prostate biopsies for men presenting in the diagnostic gray zone (when PSA levels are between 4-10 ng/mL), when phi testing was included in their overall, routine, clinical assessments.

AUA 2018 visitors to booth #2143 will discover how the phi test:

• May reduce biopsies and provide more confidence in biopsy decisions*
• Fits into the National Comprehensive Cancer Network (NCCN) recommendations for early detection of prostate cancer
• Offers both health benefits and economic value, as demonstrated in more than 80 published clinical papers and meeting abstracts

*In men age 50 years and older with total PSA results in the 4–10 ng/mL range and with digital rectal examination findings that are not suspicious for cancer.